Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Verici Dx's Sloan Ratio for the quarter that ended in Jun. 2024 was 8.11%.
As of Jun. 2024, Verici Dx has a Sloan Ratio of 8.11%, indicating the company is in the safe zone and there is no funny business with accruals.
Verici Dx Sloan Ratio % Historical Data
The historical data trend for Verici Dx's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Verici Dx's Sloan Ratio %
For the Diagnostics & Research subindustry, Verici Dx's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Verici Dx's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Verici Dx's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Verici Dx's Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was -3.461 (Dec. 2023 ) + -1.348 (Jun. 2024 ) = $-4.81 Mil.
Verici Dx's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was -2.394 (Dec. 2023 ) + -3.177 (Jun. 2024 ) = $-5.57 Mil.
Verici Dx's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2024 was -0.125 (Dec. 2023 ) + -0.095 (Jun. 2024 ) = $-0.22 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (OTCPK:VRCDF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2024, Verici Dx has a Sloan Ratio of 8.11%, indicating the company is in the safe zone and there is no funny business with accruals.
Verici Dx Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Verici Dx's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRCDF has been successfully added to your